Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA molecules, 20-25 nucleotides in length, that play a variety of roles in biology. Most notably, siRNA is involved in the RNA interference (RNAi) pathway, where it interferes with the expression of a specific gene. In addition to their role in the RNAi pathway, siRNAs also act in RNAi-related pathways, e.g., as an antiviral mechanism or in shaping the chromatin structure of a genome; the complexity of these pathways is only now being elucidated.
Researchers explore the United States public funding for the development of COVID-19 mRNA vaccines.
In a recent article published in the journal Nutrition, researchers in Australia summarized how diet could help decrease low-density lipoprotein cholesterol (LDLc) or triglyceride concentrations in polygenic hypercholesterolemia.
In a recent study posted to the bioRxiv* preprint server, researchers cloned and functionally characterized the virus ribonucleic acid (RNA) sensor, retinoic acid-inducible gene-I (RIG-I), from the microbat Myotis daubentonii (Yangochiroptera suborder) and the megabat Rousettus aegyptiacus (Yinpterochiroptera suborder), and compared them to the human ortholog.
Scientists have described the utility of gram-negative bacteria-derived outer membrane vesicles as vaccines and methods to expand their applications.
Discussed the current research on the role of molecular mechanisms in mediating immune priming in insects and regulating vector-borne disease transmission.
University of Central Florida researchers have created unique technology for treating osteoporosis that uses nanobubbles to deliver treatment to targeted areas of a person's body.
University of Pittsburgh researchers have designed cancer-fighting nanoparticles that co-deliver a chemotherapy drug and a novel immunotherapy, according to a new Nature Nanotechnology study published today.
The International Vaccine Institute announced on November 10 it signed a memorandum of understanding (MOU) with Lemonex, a company specializing in RNA gene therapy development, and agreed to seek cooperation in research and development.
Researchers reviewed technology advancements that will unlock the promise of biologically targeted messenger ribonucleic acid (mRNA) therapeutics beyond vaccines.
Despite recent advancements in our knowledge of the pathogenic mechanisms of ulcerative colitis, there is still a considerable unmet medical need for the treatment of ulcerative colitis.
This new article publication from Acta Pharmaceutica Sinica B, discusses targeting a novel inducible GPX4 alternative isoform to alleviate ferroptosis and treat metabolic-associated fatty liver disease.
Epidemics and pandemics have been frightening the human chase again and again. SARS, H1N1, Ebola, and more have exposed their real face in the past, but with every such outbreak.
An experimental drug therapy protects mice from sudden death due to the rupture of a major blood vessel in the abdomen, according to a study from researchers at Washington University School of Medicine in St. Louis.
A recent study reviewed the existing treatment modalities, including vaccines and antivirals, for SARS-CoV-2 infection.
In a new study, the effectiveness of low low-density lipoprotein cholesterol levels in reducing the risk of atherosclerotic vascular events was explored.
As they grow, solid tumors surround themselves with a thick, hard-to-penetrate wall of molecular defenses. Getting drugs past that barricade is notoriously difficult.
Small interfering RNAs, or siRNAs, hold promise to treat tumors, through their ability to specifically knock down oncogenes that promote tumor growth, without the toxicity that accompanies chemotherapy. However, the siRNAs need a delivery vehicle to protect them from degradation and clearance on their journey through the bloodstream to the cancer tumor.
In health care, perhaps no word sends a more chilling message than "cancer." Brain tumors, for example, prove especially resistant to current treatments. Only 5% of patients with that condition survive more than three years and the median survival time is 10 to 14 months.
The development of messenger RNA (mRNA) vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has only increased the impetus in this field.
Researchers investigated COVID-19-triggered changes in the levels of cyclins and cyclin-dependent kinases inside host cells.